Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SSGJ-610 in Healthy Subjects
NCT04445038Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of 610 in eosinophilic asthma (EA) (7 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Maximum Plasma Concentration up to 84 days, Time to Maximum Plasma Concentration up to 84 days and 5 more. Status: unknown.
02
Drugs
610
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04445038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445038.